Overview

This trial is active, not recruiting.

Conditions ciliary body and choroid melanoma, medium/large size, ciliary body and choroid melanoma, small size, iris melanoma, recurrent intraocular melanoma
Treatments recombinant interferon alfa-2b, dacarbazine, laboratory biomarker analysis
Phase phase 2
Sponsor Case Comprehensive Cancer Center
Start date November 2009
End date March 2017
Trial size 36 participants
Trial identifier NCT01100528, CASE2609, NCI-2010-00640

Summary

RATIONALE: Drugs used in chemotherapy, such as dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Recombinant interferon alfa-2b may interfere with the growth of tumor cells. Giving interferon alfa-2b together with dacarbazine may be an effective treatment for primary uveal melanoma.

PURPOSE: This phase II trial is studying how well giving dacarbazine together with recombinant interferon alfa-2b works in treating patients with primary uveal melanoma with genetic imbalance.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Patients receive dacarbazine IV on days 1 and 29. Beginning 4 weeks after the second dose of dacarbazine, patients receive recombinant interferon alfa-2b subcutaneously 3 times a week for 24 weeks in the absence of disease progression or unacceptable toxicity.
recombinant interferon alfa-2b Alfatronol
Given SC 3 times a week for 24 weeks
dacarbazine Asercit
Given IV on days 1 and 29
laboratory biomarker analysis
Correlative studies obtained prior to therapy, every 8 weeks while on therapy, and then every 6 months during follow-up

Primary Outcomes

Measure
Disease-free survival(DFS)
time frame: 2 yrs from start of treatment

Secondary Outcomes

Measure
Side effects and safety as assessed by NCI CTCAE version 3.0
time frame: 3 times a week for 24 weeks in the absence of unacceptable toxicity
Changes in plasma biomarkers and their association with DFS
time frame: 2 yrs from start of treatment

Eligibility Criteria

Male or female participants of any age.

Inclusion - Patients must have a diagnosis, either cytologic or histologic, of melanoma of the iris, ciliary body and/or choroid - Patient's tumor must exhibit monosomy 3 and/or 8q amplification as determined by karyotype, CGH, PCR-based microsatellite, and/or FISH analysis; tissue or cells for analysis can be obtained at enucleation, resection, or by FNA - Patients must have undergone adequate primary therapy; this can include enucleation, brachytherapy, proton beam radiotherapy, stereotactic irradiation, trans-scleral local resection, transretinal resection or diode laser thermotherapy - Patients must have had chest X-ray and hepatic ultrasound or other imaging methods such as CT or MRI to eliminate distant disease - Patients must have a performance status (ECOG) of < 2 - Patients must be entered within 56 days of completing primary therapy - WBC >= 3.0 x 10^9/L - Neutrophils >= 1.5 x 10^9/L - Platelets >= 100 x 10^9/L - INR and PTT < 1.5 x upper limit of normal - Hemoglobin >= 10 gm/100 ml - Creatinine =< 2 mg/dl - Bilirubin (total) =< 1.5 mg/dl - ALT =< 1.5 x upper limit of normal - Alkaline phosphatase =< 1.5 x upper limit of normal - AST =< 1.5 x upper limit of normal - Patients must not have received any other systemic therapy for melanoma - Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately - All patients must be informed of the investigational nature of this study and must provide written informed consent in accordance with institutional and federal guidelines; a copy of the informed consent document signed by the patient must be given to the patient Exclusion - Patients with metastasis - Patients that are pregnant or breastfeeding - Patients may not be receiving any other investigational agents - Patients with a history of immunodeficiency or autoimmune diseases are not eligible; patients requiring therapy with corticosteroids or other immunosuppressives are not eligible; patients requiring ongoing replacement therapy with physiologic doses of corticosteroids will be eligible. - Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements are not eligible - Patients who are known to be positive for HIV or HepBAg - No patient may have had a malignancy other than a malignant melanoma, with the following exceptions: basal or squamous cell carcinomas of the skin; carcinoma in-situ of the uterine cervix; any malignancy treated with curative intent and in complete remission for > 3 years - Patients with organ allografts

Additional Information

Official title Adjuvant Therapy for Patients With Primary Uveal Melanoma With Genetic Imbalance
Principal investigator Pierre Triozzi
Description PRIMARY OBJECTIVES: I. Assess disease-free survival (DFS) with sequential dacarbazine and interferon-alfa-2b as an adjuvant to primary therapy for patients with uveal melanoma with genetic imbalance. SECONDARY OBJECTIVES: I. Evaluate side effects and assess safety in the patient population. II. Examine the relationship between the levels of plasma biomarkers of immune function and tumor invasion and the clinical outcome. OUTLINE: Patients receive dacarbazine IV on days 1 and 29. Beginning 4 weeks after the second dose of dacarbazine, patients receive recombinant interferon alfa-2b subcutaneously 3 times a week for 24 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 6 months.
Trial information was received from ClinicalTrials.gov and was last updated in March 2016.
Information provided to ClinicalTrials.gov by Case Comprehensive Cancer Center.